Health economics of disease-modifying therapy for multiple sclerosis in the United States

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price i...

Full description

Bibliographic Details
Main Author: Daniel M. Hartung
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756286420987031
id doaj-d087b5f5b12e4b129e129f1145e9ee12
record_format Article
spelling doaj-d087b5f5b12e4b129e129f1145e9ee122021-02-17T17:03:44ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642021-02-011410.1177/1756286420987031Health economics of disease-modifying therapy for multiple sclerosis in the United StatesDaniel M. HartungMultiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.https://doi.org/10.1177/1756286420987031
collection DOAJ
language English
format Article
sources DOAJ
author Daniel M. Hartung
spellingShingle Daniel M. Hartung
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Therapeutic Advances in Neurological Disorders
author_facet Daniel M. Hartung
author_sort Daniel M. Hartung
title Health economics of disease-modifying therapy for multiple sclerosis in the United States
title_short Health economics of disease-modifying therapy for multiple sclerosis in the United States
title_full Health economics of disease-modifying therapy for multiple sclerosis in the United States
title_fullStr Health economics of disease-modifying therapy for multiple sclerosis in the United States
title_full_unstemmed Health economics of disease-modifying therapy for multiple sclerosis in the United States
title_sort health economics of disease-modifying therapy for multiple sclerosis in the united states
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2864
publishDate 2021-02-01
description Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.
url https://doi.org/10.1177/1756286420987031
work_keys_str_mv AT danielmhartung healtheconomicsofdiseasemodifyingtherapyformultiplesclerosisintheunitedstates
_version_ 1724264932205133824

Similar Items